Seres Therapeutics

1 serious warning sign in Seres Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 5 Aug 2026 and 8 later 8-Ks.

• Doubt it can keep going

  Serious

  The company or its auditor warned it may not have enough money to last the next year.

  “These conditions raise substantial doubt about the Company’s ability to continue as a going concern.”

  Show the full paragraph

  Primarily as a result of the costs associated with the discovery and development of novel live biotherapeutics, the Company incurred a net loss from operations of $ 42,180 for the six months ended June 30, 2026 . The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. Based on the Company’s currently available cash resources, the $ 12,500 Milestone Termination Payment (as defined below in Note 3, Discontinued Operations and TSA ) received from SPN (as defined below) in July 2026, and the expected receipt of the additional $ 12,500 Milestone Termination Payment due from SPN in October 2026 , current and forecasted level of operations, and forecasted cash flows for the 12-month period subsequent to the date of issuance of these condensed consolidated financial statements, the Company will require additional funding to support its ongoing operations and meet its obligations as they come due. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

  From the 10-Q filed 5 August 2026, Part I, Item 1. Financial Statements. Read it in the filing